Publications by authors named "Peter Rix"

Claim this Profile
C
Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models.
Liliana Soroceanu, Eric Singer, Pratiksha Dighe, Max Sidorov, Chandani Limbad, Peter Rix

Neurooncol Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Steven P Govek, Celine Bonnefous, Jackaline D Julien, Johnny Y Nagasawa, Mehmet Kahraman, Peter J Rix

Bioorg Med Chem Lett· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Peter J Rix

Elife· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.
Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, Andiliy Lai, Celine Bonnefous, Peter J Rix

ACS Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Johnny Nagasawa, Steven Govek, Mehmet Kahraman, Andiliy Lai, Celine Bonnefous, Peter J Rix

J Med Chem· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
Thuc M Le, Soumya Poddar, Joseph R Capri, Evan R Abt, Woosuk Kim, Peter Rix

Nat Commun· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Peter J Rix

Elife· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Steven P Govek, Johnny Y Nagasawa, Karensa L Douglas, Andiliy G Lai, Mehmet Kahraman, Peter J Rix

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Andiliy Lai, Mehmet Kahraman, Steven Govek, Johnny Nagasawa, Celine Bonnefous, Peter J Rix

J Med Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects.
Peter J Rix, Andrew Vick, Neil J Attkins, Geoffrey E Barker, Adrian W Bott

Clin Pharmacokinet· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 26-Week Toxicity Assessment of AIR001 (Sodium Nitrite) by Inhalation Exposure in Rats and by Intravenous Administration in Dogs.
Jeffrey Tepper, Ricardo Ochoa, Peter Rix, Gary Elliott, Niel Hoglen

Int J Toxicol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Dana E Rathkopf, Michael J Morris, Josef J Fox, Daniel C Danila, Susan F Slovin, Peter J Rix

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARN-509: a novel antiandrogen for prostate cancer treatment.
Nicola J Clegg, John Wongvipat, James D Joseph, Chris Tran, Samedy Ouk, Peter J Rix

Cancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors.
Sergio G Durón, Andrew Lindstrom, Céline Bonnefous, Hui Zhang, Xiaohong Chen, Peter Rix

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases.
Kent T Symons, Phan M Nguyen, Mark E Massari, John V Anzola, Lena M Staszewski, Peter J Rix

J Pharmacol Exp Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.
Joseph E Payne, Céline Bonnefous, Kent T Symons, Phan M Nguyen, Marciano Sablad, Peter Rix

J Med Chem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
Mark R Herbert, Dana L Siegel, Lena Staszewski, Charmagne Cayanan, Urmi Banerjee, Peter Rix

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
Céline Bonnefous, Joseph E Payne, Jeffrey Roppe, Hui Zhuang, Xiaohong Chen, Peter Rix

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.
Eric G Vajda, Francisco J López, Peter Rix, Robert Hill, Yanling Chen

J Pharmacol Exp Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.
Esther Martinborough, Yixing Shen, Arjan van Oeveren, Yun Oliver Long, Thomas L S Lau, Peter J Rix

J Med Chem· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis